A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Listed as NCT04344158, this PHASE3 trial focuses on Advanced Hepatocellular Carcinoma (HCC) and remains ongoing. Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
▶ Show 2 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
May 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baoji, China , Beijing, China , Bengbu, China , Changchun, China , Changsha, China , Chengde, China , Chengdu, China , Chongqing, China , Fuzhou, China , Gansu, China and 35 more locations